Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

PHASE1RECRUITING

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7. 1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

info
Simpliy with AI

Study details:

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301 (cosibelimab), a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months of visits with survival follow-up for select cohorts). Following the dose escalation portion of the study, additional evaluable subjects may be included in order to further characterize safety and efficacy at selected doses and/or in specific patient sub-groups.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Signed written informed consent.
  • Male or female subjects aged greater than or equal to 18 years.
  • For NSCLC: Histologically or cytologically confirmed diagnosis of unresectable recurrent or metastatic non-small cell lung cancer.
  • For CRC: Histologically confirmed diagnosis of recurrent or metastatic colorectal cancer assessed as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
  • For EC: Histologically or cytologically confirmed advanced, recurrent or metastatic endometrial carcinoma.
  • For cSCC: Histologically confirmed diagnosis of unresectable or metastatic cutaneous squamous cell carcinoma not amenable to local therapy.
  • For SCLC: Histologically or cytologically confirmed diagnosis of unresectable small cell lung cancer.
  • For MPM: Histologically or cytologically confirmed diagnosis of unresectable malignant pleural or peritoneal mesothelioma.
  • For HNSCC: Histologically or cytologically confirmed diagnosis of recurrent or metastatic HNSCC (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).
  • For MEL: Histologically confirmed diagnosis of unresectable Stage III or metastatic melanoma not amenable to local therapy (excluding uveal or ocular melanoma).
  • For MCC: Histologically confirmed diagnosis of metastatic Merkel cell carcinoma not amenable to local therapy.
  • For RCC: Histologically confirmed diagnosis of renal cell carcinoma (with clear cell component) with advanced or metastatic disease that is not amenable to cure by surgery or other means.
  • For UC: Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, urethra) not amenable to cure by surgery or other means.
  • For HL: Histologically confirmed primary diagnosis of classical Hodgkin's lymphoma.
  • For B-cell NHL: Histologically confirmed diagnosis of non-Hodgkin lymphoma.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months.
  • Must have at least one measurable lesion based on RECIST 1.1.
  • Have provided a formalin fixed tumor tissue sample from a biopsy of a tumor lesion either at the time of or after the diagnosis of metastatic disease has been made AND from a site not previously irradiated.
  • Adequate hematological, hepatic and renal function as defined in the protocol.
  • Effective contraception for both male and female subjects if the risk of conception exists.
  • Other protocol defined inclusion criteria could apply.
  • Exclusion criteria

  • Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  • Concurrent treatment with a non-permitted drug.
  • History of severe hypersensitivity reactions to other monoclonal antibodies.
  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, or localized prostate cancer.
  • Chemotherapy, radioactive, biological cancer therapy, or tyrosine kinase inhibitor (TKI) therapy, within four weeks prior to the first dose of study drug, or who has not recovered to NCI CTCAE Grade 1 or better from the AEs due to cancer therapeutics administered more than four weeks earlier.
  • Significant acute or chronic infections as defined in the protocol.
  • Active or history of interstitial lung disease (ILD), or has had a history of pneumonitis that has required oral or IV steroids.
  • Active or suspected autoimmune disease or a documented history of autoimmune disease.
  • Known current drug or alcohol abuse.
  • Underlying medical conditions that will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.
  • Use of other investigational therapy within 28 days before study drug administration.
  • Pregnant or breastfeeding.
  • Uncontrolled or significant cardiovascular disease.
  • Psychiatric illness or social situation that would preclude study compliance.
  • Receipt of live, attenuated vaccine within 28 days prior to the first dose of study drug.
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2017-09-20

    Primary completion: 2021-11-18

    Study completion finish: 2024-12-01

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT03212404

    Intervention or treatment

    DRUG: CK-301 (cosibelimab)

    Conditions

    • Carcinoma, Non-Small-Cell Lung
    • Head and Neck Cancer
    • Melanoma
    • Merkel Cell Carcinoma
    • Renal Cell Carcinoma
    • Urothelial Carcinoma
    • Classical Hodgkin Lymphoma
    • Cutaneous Squamous Cell Carcinoma
    • Endometrial Cancer
    • Lung Neoplasms
    • Carcinoma, Small Cell
    • Malignant Mesothelioma, Advanced
    • Non Hodgkin Lymphoma
    Image related to Carcinoma, Non-Small-Cell Lung
    • Condition: Carcinoma, Non-Small-Cell Lung, Head and Neck Cancer and more

    • DRUG: CK-301 (cosibelimab)

    • South Brisbane, Queensland, Australia and more

    • Sponsor: Checkpoint Therapeutics, Inc.

    Find a site

    Closest Location:

    Research Site

    Research sites nearby

    Select from list below to view details:

    • Research Site

      South Brisbane, Queensland, Australia

    • Research Site

      Woolloongabba, Queensland, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: CK-301 (cosibelimab)
    • Part 1 - Dose Escalation; Part 2 - Dose Expansion
    DRUG: CK-301 (cosibelimab)
    • CK-301 will be administered in periods of 28-day cycles.

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Dose Limiting ToxicityNot SpecifiedUp to 4 weeks
    Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version)Not SpecifiedScreening through 4 weeks after study completion, an average of 6 months
    Confirmed Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)Not SpecifiedPart 2 Only: Average of 6 months

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Confirmed Best Overall Response (BOR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)Not SpecifiedEvery 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
    Duration of Response (DoR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)Not SpecifiedEvery 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
    Objective response rate and duration of response (DOR) based on Modified RECIST 1.1 for immune based therapeuticsNot SpecifiedPart 2 Only: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
    Overall Survival (OS)Not SpecifiedPart 2 Only: Every 8 weeks for first 32 weeks, then 12 weeks through study completion, an average of 6 months
    Pharmacokinetic parameter: AUC (0-t) of CK-301Not SpecifiedBaseline up to 12 weeks after study completion, an average of 6 months
    Pharmacokinetic parameter: AUC (0-infinity) of CK-301Not SpecifiedBaseline up to 12 weeks after study completion, an average of 6 months
    Pharmacokinetic parameter: Cmax of CK-301Not SpecifiedBaseline up to 12 weeks after study completion, an average of 6 months
    Pharmacokinetic parameter: Tmax of CK-301Not SpecifiedBaseline up to 12 weeks after study completion, an average of 6 months
    Pharmacokinetic parameter: T(1/2) of CK-301Not SpecifiedBaseline up to 12 weeks after study completion, an average of 6 months
    Number of subjects with anti-CK-301 antibodiesNot SpecifiedBaseline up to 12 weeks after study completion, an average of 6 months

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

    Other trails to consider

    Top searched conditions